Skip to search formSkip to main contentSkip to account menu

SR-2508

Known as: SR 2508, SR2508 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Etanidazole

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1998
1998
Survival results from a phase I study of etanidazole (SR2508) and radiotherapy in patients with malignant glioma.
1998
1998
Intervention with the hypoxic tumor cell sensitizer etanidazole in the combined modality treatment of limited stage small-cell lung cancer. A one-institution study.
1989
1989
Characteristics of fluorinated nitroazoles as hypoxic cell radiosensitizers.
1989
1989
Importance of tumor affinity of nitroazoles in hypoxic radiosensitization.
Highly Cited
1987
Highly Cited
1987
Relationship between the neurotoxicity of the hypoxic cell radiosensitizer SR 2508 and the pharmacokinetic profile.
Complete pharmacological data from 71 patients treated on the phase I trial of SR 2508 were analyzed to see if the dose-limiting… 
Highly Cited
1987
Highly Cited
1987
Failure of misonidazole-sensitized radiotherapy to impact upon outcome among stage III-IV squamous cancers of the head and neck.
Review
1986
Review
1986
Sensitizers and radiation dose fractionation: results and interpretations.
1985
1985
The in vitro sensitivity of chronically hypoxic EMT6/SF cells to X-radiation and hypoxic cell radiosensitizers.
We have investigated the effect of extreme, prolonged hypoxia on the radiosensitivity of EMT6/SF cells in vitro. As cells were… 
Review
1984
Review
1984
Clinical trials with hypoxic cell sensitizers: time to retrench or time to push forward?
1982
1982
Enhanced cytotoxicity of melphalan by prolonged exposure to nitroimidazoles: the role of endogenous thiols.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)